// App-Quantinova.ai

10023 : Do risks with the use of erythropoeitin stimulating agents (ESAs) differ by tumor type? Implications concerning survival and thrombosis based on meta-analysis (MA).

Researchers

Presenter

  • Vineeth Sukrithan

Principal Investigators

  • Richard J. Gralla

Medical Centers

  • Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

  • Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Solid malignancies

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved